Linezolid: Difference between revisions
(Blanked the page) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Linezolid}} | |||
{{CMG}}; {{AE}} {{chetan}} | |||
==Overview== | |||
'''Linezolid''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[lɪnɛˈzəlɪd]}}) is a synthetic [[antibiotic]], the first of the [[oxazolidinone]] class, used for the treatment of infections caused by multi-resistant [[bacteria]] including [[streptococcus]] and [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA). It is marketed under the trade name '''Zyvox''' (or '''Zyvoxid''' in [[Europe]]) ([[Pfizer, Inc.|Pfizer]]). | |||
It was the first commercially available [[oxazolidinone]] antibiotic and is usually reserved for the treatment of serious [[bacteria|bacterial]] infections where older antibiotics have failed due to [[antibiotic resistance]]. Conditions such as skin infections or nosocomial [[pneumonia]] where [[methicillin]] or [[penicillin]] resistance is found are indicators for linezolid use. Compared to the older antibiotics it is quite expensive. | |||
The drug works by inhibiting the initiation of bacterial protein synthesis. Initially there was hope that bacteria would be unable to develop resistance to it. However, in 2001 ''[[Staphylococcus aureus]]'' was first identified as being resistant to linezolid.<ref>Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001 Jul 21;358(9277):207-8.</ref> Linezolid is effective against [[gram-positive]] pathogens, notably ''[[Enterococcus faecium]]'', ''Staphylococcus aureus'', ''[[Streptococcus agalactiae]]'', ''[[Streptococcus pneumoniae]]'', and ''[[Streptococcus pyogenes]]''. It has almost no effect on gram-negative bacteria and is only [[bacteriostatic]] against most [[Enterococcus]] species. | |||
Linezolid has been used to treat [[Tuberculosis treatment|tuberculosis]].<ref name="Lippea2006">{{cite journal | journal=J Infect | volume=52 | issue=2 | year=2006 | pages=92–6 | doi=10.1016/j.jinf.2005.04.007 | title=Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases | author=von der Lippea B, Sandvenb P, Brubakk O. }}</ref> | |||
The oxazolidinone class was discovered by researchers at E.I. duPont de Nemours and reported in [[1987]]. [[Upjohn]] developed linezolid (Upjohn is now part of [[Pfizer]]) and [[Food and Drug Administration]] (FDA) approval was granted in [[April]] of [[2000]]. It is sold in the U.S. under the tradename '''Zyvox''' in either tablet form, oral suspension powder, or in an inactive medium for intravenous injection. | |||
==Category== | |||
Oxazolidinone | |||
==US Brand Names== | |||
Oxazolidinone<sup>®</sup> | |||
==FDA Package Insert== | |||
''' [[Linezolid description|Description]]''' | |||
'''| [[Linezolid clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Linezolid microbiology|Microbiology]]''' | |||
'''| [[Linezolid indications and usage|Indications and Usage]]''' | |||
'''| [[Linezolid contraindications|Contraindications]]''' | |||
'''| [[Linezolid warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Linezolid adverse reactions|Adverse Reactions]]''' | |||
'''| [[Linezolid drug interactions|Drug Interactions]]''' | |||
'''| [[Linezolid overdosage|Overdosage]]''' | |||
'''| [[Linezolid clinical studies|Clinical Studies]]''' | |||
'''| [[Linezolid dosage and administration|Dosage and Administration]]''' | |||
'''| [[Linezolid how supplied|How Supplied]]''' | |||
'''| [[Linezolid labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
Linezolid works on the initiation of protein synthesis. It does this by stopping the [[30S]] and [[50S]] subunit from binding together. Linezolid binds on the 23S portion of the 50S subunit close to the peptidyl transferase and [[chloramphenicol]] binding sites. This then stops the interaction with the 30S subunit. | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 03:31, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Linezolid (INN) (IPA: Template:IPA) is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). It is marketed under the trade name Zyvox (or Zyvoxid in Europe) (Pfizer).
It was the first commercially available oxazolidinone antibiotic and is usually reserved for the treatment of serious bacterial infections where older antibiotics have failed due to antibiotic resistance. Conditions such as skin infections or nosocomial pneumonia where methicillin or penicillin resistance is found are indicators for linezolid use. Compared to the older antibiotics it is quite expensive.
The drug works by inhibiting the initiation of bacterial protein synthesis. Initially there was hope that bacteria would be unable to develop resistance to it. However, in 2001 Staphylococcus aureus was first identified as being resistant to linezolid.[1] Linezolid is effective against gram-positive pathogens, notably Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, and Streptococcus pyogenes. It has almost no effect on gram-negative bacteria and is only bacteriostatic against most Enterococcus species. Linezolid has been used to treat tuberculosis.[2]
The oxazolidinone class was discovered by researchers at E.I. duPont de Nemours and reported in 1987. Upjohn developed linezolid (Upjohn is now part of Pfizer) and Food and Drug Administration (FDA) approval was granted in April of 2000. It is sold in the U.S. under the tradename Zyvox in either tablet form, oral suspension powder, or in an inactive medium for intravenous injection.
Category
Oxazolidinone
US Brand Names
Oxazolidinone®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Linezolid works on the initiation of protein synthesis. It does this by stopping the 30S and 50S subunit from binding together. Linezolid binds on the 23S portion of the 50S subunit close to the peptidyl transferase and chloramphenicol binding sites. This then stops the interaction with the 30S subunit.
References
- ↑ Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001 Jul 21;358(9277):207-8.
- ↑ von der Lippea B, Sandvenb P, Brubakk O. (2006). "Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases". J Infect. 52 (2): 92&ndash, 6. doi:10.1016/j.jinf.2005.04.007.